Stem Cell Deep Dive; ‘Close to a Cure’; Possible Cut in Medicare Cancer Payments

Diet-related changes in the gut microbiome may play a role in the evolution of aggressive forms of prostate cancer, suggesting dietary changes have a role in prevention. (Cleveland Clinic)

A new study will use advanced imaging techniques and artificial intelligence in new-onset diabetes as part of a strategy to improve early diagnosis of pancreatic cancer. (Baylor College of Medicine)

A documentary examines the science and the life-altering potential of stem cell therapy. (The Guardian)

Younger patients with B-cell non-Hodgkin lymphoma may have an increased risk of developing age-related diseases, including kidney and lung conditions. (American Association for Cancer Research)

AstraZeneca CEO Pascal Soriot expressed confidence that “we are very close to a cure” for several types of cancer. (CNBC)

The American College of Surgeons elected E. Christopher Ellison, MD, a general surgeon at Ohio State University in Columbus, as president elect for 2021-2022.

A low number of tumor mutations was associated with improved response to immune checkpoint inhibitors in preclinical models of breast and kidney cancers. (University of Texas MD Anderson Cancer Center, Science Translational Medicine)

Two old and seemingly unrelated therapies produced encouraging activity in preclinical studies of pediatric medulloblastoma. (Johns Hopkins Health, Catholic University of the Sacred Heart)

Already established for treatment of breast, ovarian, and prostate cancers, a PARP inhibitor will be investigated as initial treatment for patients with newly diagnosed glioblastoma. (University of California San Francisco)

Medicare payments for cancer care will decrease by 5%, according to the latest version of the 2022 Medicare Physician Fee Schedule. (American Society of Clinical Oncology)

From a federal prison in Fort Worth, Texas, Netflix documentary star Joe Exotic announced via Twitter that he has an aggressive form of prostate cancer. (AP News)

The American Society of Clinical Oncology published its initial guideline for managing immune-related adverse events (IRAEs) associated with CAR T-cell therapy and an update to its guideline for managing IRAEs in patients treated with immune checkpoint inhibitors.